Clinical Trial: NCT04318938
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Information Provided By: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Last Update Posted: | 2026-06-23 |
Study Overview
Brief Summary
This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
Official Title
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Conditions
NSCLC
Intervention / Treatment
- Drug: Brigatinib
- Drug: Tyrosine kinase inhibitor
Other Study ID Numbers
- ABP
Start Date (Actual)
2020-03-30
Primary Completion Date (Actual)
2026-05-30
Study Completion Date (Actual)
2026-05-30
Enrollment (Actual)
118
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Information Provided By: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Last Update Posted: | 2026-06-23 |
Study Overview
Brief Summary
This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
Official Title
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Conditions
NSCLC
Intervention / Treatment
- Drug: Brigatinib
- Drug: Tyrosine kinase inhibitor
Other Study ID Numbers
- ABP
Start Date (Actual)
2020-03-30
Primary Completion Date (Actual)
2026-05-30
Study Completion Date (Actual)
2026-05-30
Enrollment (Actual)
118
Study Type
Interventional
Phase
Phase 2